{"name":"Revolution Medicines","slug":"revolution","ticker":"RVMD","exchange":"NASDAQ","domain":"revmed.com","description":"Revolution Medicines is a clinical-stage oncology biotech company focused on developing novel small molecule therapies for cancer. The company's pipeline includes several promising candidates, including RMC-4630 and RMC-6291. Revolution Medicines has established partnerships with leading pharmaceutical companies to accelerate the development of its pipeline. With a strong focus on precision medicine, the company aims to improve treatment outcomes for patients with cancer.","hq":"Redwood City, CA","founded":2014,"employees":"~75","ceo":"Mark Goldsmith","sector":"Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":987332000,"netIncome":-1131301000,"cash":383745000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"RMC-4630 patent cliff ($0.0B at risk)","drug":"RMC-4630","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Elironrasib","genericName":"Elironrasib","slug":"elironrasib","indication":"Other","status":"phase_1"},{"name":"Zoldonrasib","genericName":"Zoldonrasib","slug":"zoldonrasib","indication":"Other","status":"phase_1"},{"name":"RMC-9805","genericName":"RMC-9805","slug":"rmc-9805","indication":"Other","status":"phase_1"},{"name":"daraxonrasib","genericName":"daraxonrasib","slug":"daraxonrasib","indication":"Other","status":"phase_3"},{"name":"mFOLFOX6 regimen","genericName":"mFOLFOX6 regimen","slug":"mfolfox6-regimen","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"RMC-6236","genericName":"RMC-6236","slug":"rmc-6236","indication":"Non-small cell lung cancer with KRAS G12C mutation","status":"phase_3"},{"name":"mFOLFIRINOX regimen","genericName":"mFOLFIRINOX regimen","slug":"mfolfirinox-regimen","indication":"Metastatic pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"Elironrasib","genericName":"Elironrasib","slug":"elironrasib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zoldonrasib","genericName":"Zoldonrasib","slug":"zoldonrasib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RMC-6236","genericName":"RMC-6236","slug":"rmc-6236","phase":"phase_3","mechanism":"RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.","indications":["Non-small cell lung cancer with KRAS G12C mutation","Colorectal cancer with KRAS G12C mutation","Other solid tumors with KRAS G12C mutation"],"catalyst":""},{"name":"RMC-9805","genericName":"RMC-9805","slug":"rmc-9805","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"daraxonrasib","genericName":"daraxonrasib","slug":"daraxonrasib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"mFOLFIRINOX regimen","genericName":"mFOLFIRINOX regimen","slug":"mfolfirinox-regimen","phase":"phase_3","mechanism":"mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","indications":["Metastatic pancreatic cancer","Metastatic colorectal cancer","Gastric cancer","Biliary tract cancer"],"catalyst":""},{"name":"mFOLFOX6 regimen","genericName":"mFOLFOX6 regimen","slug":"mfolfox6-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Revolution Medicines Announces FDA Clearance of Investigational New Drug (IND) Application for RMC-6291","summary":"Revolution Medicines announced that the FDA has cleared the IND application for RMC-6291, enabling the company to initiate a Phase 1 clinical trial.","drugName":"RMC-6291","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Revolution Medicines Reports Third Quarter 2023 Financial Results","summary":"Revolution Medicines reported its third quarter 2023 financial results, highlighting progress in its pipeline and financial position.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Revolution Medicines Announces Collaboration with Pfizer to Develop Novel Cancer Therapies","summary":"Revolution Medicines announced a collaboration with Pfizer to develop novel cancer therapies, expanding its pipeline and partnerships.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRW1LWUkycHB6cFdVS3I1WHlkRVE0Mm8wclhBVFJmdi1hUlJsSTJSUDR3YnNjdXVVOHYwSmQtXzJOVWc2TlBxWEctbFVseFVQdW1PSi1NRFdhb1ZOcE9ybU5MNWhkYjhrMlIzcXpid3B1bkVjRTlQdkVHcmVNclJsaVpNR2xvY1ZVWFhneTBSZGZ3ZUFYeWNybTJrZlVvdjV1bHU1TFQySmE?oc=5","date":"2026-02-02","type":"pipeline","source":"The Pharma Letter","summary":"Merck walks away from Revolution talks as price gap bites - The Pharma Letter","headline":"Merck walks away from Revolution talks as price gap bites","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbjBacWlIMmVHdGdKekJkWWVBWkVYeXhlYXBzelAwbFpGekViNGlxVGlpU09XeUhUdG1vNjk3TmY4Z2IwWjI1a2hzeFZQc2FVREx3R3U3UWJDOHV2ZFJkWUxZa2thTGVtSnU1T1l6ZVNLZHRGSkpyQjRablNibURjenF3RDJobGVpVmNJakY2dHBSTzQ4Uk5QV3puaUh2RlgweGoxeHhNNFlKQ01lV254cTdZUkQ4LWR1RHJ1VUhvekdVLVprcW5FekFCVDBHUjNzX09OMjA3QWx4eU1OYTVGR1FuUEl3WTkyekJLX3p0TVpTM2g3VGJN?oc=5","date":"2026-01-26","type":"pipeline","source":"FinancialContent","summary":"The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed - FinancialContent","headline":"The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOSi1COGJjMnJTTjdUelNyczhOcUl0c21PMjhzYnNBaHFiY0RBbTFHVmpFOWdEZjktSVdUTlRPeHRMYlVNcW11YWhZNlVWYS1pcXBYaXlmTGlJcU93eTJ6eExOTHo1NXNKWUpZNk1XbUptdXdfd3dZMlA3c2dSUVpqZXkwNUZUeEN6QTFXR2x2YlRyTDNKdXdoY21qaw?oc=5","date":"2026-01-25","type":"deal","source":"WSJ","summary":"Exclusive | Merck No Longer in Talks to Buy Revolution Medicines - WSJ","headline":"Exclusive | Merck No Longer in Talks to Buy Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNaUFld3NfNlk4czFrdUYybW5zRXRrSDVDVjl4a3lkX0U5bUI0dl9LdVg0M0R1NW1lRHZrbGdqN0N3cWZPRXJIMXVrbENlREhSZkxIOG9ZVEVscDJGUkZOVjBFYlVuRTFBTEYyN1l1dGxoOU5adk9KUng1X2lFSF9aOExzbzU4M2FB?oc=5","date":"2026-01-14","type":"deal","source":"Sherwood News","summary":"Big Pharma enters 2026 with an appetite for deals - Sherwood News","headline":"Big Pharma enters 2026 with an appetite for deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQOFliVnY4bFFWZG44Y1JIN3c3TTVWYjdDNkZjTC1NbTlCYUNCYVBMWHVTV2dyNVE2bF91Uy1LZW4yVmcwMzM5YW1iOGtseU8xblFwUGFVVEJyc3k1T0R6MDF3azVGbG5rQVNFNEtqZnFVV0VJNjgtRW1NdW1JVlRXckRPQVhMTjFJY0tWaGdaN2laallTZUZzWDJMeTZXM081dG8xX201b0o4NGprZlFBZDNvaHRZeGM?oc=5","date":"2026-01-09","type":"deal","source":"Seeking Alpha","summary":"Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle (RVMD) - Seeking Alpha","headline":"Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle (RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNRlBGS0pPVG9HXzdySU5fejI0ZFNyZ1IxVndMWXduNmFDamF0UWtaOG12Z2xxbjlWWlI4V3FYOGRURW9CQVpZN1NhUjJQVm9Xd21HS1JCUTRxejdpb2RCWGJXcTRMdnVZYW84bTUzaF9sT18ydGl0ZktYMi15RVhVWDRqX3VBeXhkR1E?oc=5","date":"2026-01-09","type":"deal","source":"Yahoo Finance","summary":"Merck in Talks to Buy Revolution Medicines Per Financial Times Report - Yahoo Finance","headline":"Merck in Talks to Buy Revolution Medicines Per Financial Times Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPOXhHRHA4OVNBZllGZWVmSWNxX1JmVTNoa3dlRVduVW1LWXUteG11QmdtUHMzVldaeHEtTW5FekUySmtLbnZEYXpwR1BReGpOTEVtVm5oSnFkMzRzVjI4UjJvRFFYOWFHeDJSU3R4MWlldlhqV3d0VFRJQVNKQWd1NlNoRXY5MG42bFpuSkl4ZmZhZjJW?oc=5","date":"2026-01-09","type":"pipeline","source":"Barron's","summary":"Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's","headline":"Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQMXlJV3g0RW1XRmQtUUZJa1lQekdQejFCRllPMWFjUUVCODd0MWpUUzlsbUYxV0sxNXF0Z0NtYjdwS280OGJmVzFxdGdfU1BXM25TVHhiWnJncG1tYTlxY3pySmxmdFA0MlF5cVhaRjhsQXotX0FDQ0lFaHFabDBJdFQwSGRHblprd3JQcjJqa0RJYTFoMDIyYVFxd3ZVZng5U0RCbEVuTnVsRGJvVmJoam4xU0YzeS1hUE9VS09BWmNZUnBjMnRJMFEtSWlTcTNPbzBVTGxIZk16Tm9pNXliQkxoUVRubUg3?oc=5","date":"2026-01-09","type":"deal","source":"Benzinga","summary":"Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga","headline":"Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOaWxzQk56UkMyRzhLdXNxSDJ2YzN2Zjl1clNYUkpNeWlBSmF1UVZNeklLQ09hU2N6SUg3QThxMkZ2cUNRUzgtYTJqaXdlT3hWX2xZdVcyNk0wc213aHJ5Wl9NMGtzY1drN1NtZGpEUlp5R0d6Tzk4eVBISi1PQ190d1pNNGE3T3JoTlBGMDViVHRJaUpBWDByYWpuaFFKSVZBLUtURVJsZ2ZLd2ItaFdKRXdSSW84LWV3eC1B?oc=5","date":"2026-01-09","type":"pipeline","source":"TipRanks","summary":"M&A News: Revolution Medicines (RVMD) Stock Rallies on News of Potential Acquisition by Merck - TipRanks","headline":"M&A News: Revolution Medicines (RVMD) Stock Rallies on News of Potential Acquisition by Merck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOX1VkUkd0cmRWcWFKRkhRTEc3d0hzSi1aYkRlenlhSFROcFZsLW9LbmJrcndsaW9NNVZHdFZTeFZWVjhwS3ZlYVNQN21HTk9lVEFpV19aQmlDZGt2Zm1BU0syWnp6aHgxTWltckhJX1NIYjFjaURfTXV6Sk45aHZYNWQtRjBvald5dnFkNmQ1M0c5TENEaTQtZExzeGFNWmFMTG85Z1BVSTRtdjZMRHVfZXg2MWF2M2RoYk50aVkxSkVpSE1IWlR4Y2lYaHBhNVRueFBLZHRyOGlfVmZISHBUWEhVX3k3S1RmeWYwSUtaOWJtZFl4MXB2QVlTeFB1STB6a0tESkpn?oc=5","date":"2026-01-08","type":"pipeline","source":"The Chronicle-Journal","summary":"The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader - The Chronicle-Journal","headline":"The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxObGZRSzFURklCemN1SW5fVUNpOFNEOHYyOURsbjFueUUzOWJmX19yNlNzZlE3cVRUdGtDLVRNcXFwR3AxMnRJVTlfNE56Y0pqU19uVWxpV3lZMkJNRG9GZ1lvYkpqSlFrUzREeHNLRklTNnhnZ2ZuZVNmdFBlN2JTR1R3X1pzYml6cE85Q3p0MGxxSTZ1TFRtWExYTDVVZ3oxSDVxSmo0SjZEVW9FSjlmMlNvcE80bGRidE43RC1aSTZiMmZTSGc?oc=5","date":"2026-01-08","type":"deal","source":"Stocktwits","summary":"Merck Looks To Buy Cancer Drugmaker Revolution Medicines As Keytruda Nears Patent Expiry: Report - Stocktwits","headline":"Merck Looks To Buy Cancer Drugmaker Revolution Medicines As Keytruda Nears Patent Expiry: Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQUkVPV3E1eWh0ekxxbENpNEhlMDRPUFBKbnRLMlpaSXNISFpyQzJwMlBkQWRFM0liRGo2QzRMcENGa0RuMmNkSFI5akNTQUQwU3hrSW85RzA0Zm1sRUJFYVVYVHVDOVhUUFQ4a2xTSGRFeFp2a19kdnlLVUZVZExyNVBveXJoVjBUYkg1X0ZmMlRuOHZDanhvUUF4dndxdW9Gbnp6cHBZakpIMnpSWC10WlVsLXc4dEpNcFZsSjRKWGFQOWdnUi14TQ?oc=5","date":"2026-01-07","type":"deal","source":"Reuters","summary":"AbbVie denies media reports of talks to buy Revolution Medicines - Reuters","headline":"AbbVie denies media reports of talks to buy Revolution Medicines","sentiment":"neutral"}],"patents":[{"drugName":"RMC-4630","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_1":3,"phase_3":3,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":11580000,"period":"2023-12-31"},{"value":35380000,"period":"2022-12-31"},{"value":29390000,"period":"2021-12-31"},{"value":42983000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":987332000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1131301000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":383745000,"cashHistory":[],"totalAssets":2354508000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}